{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:22:39Z","timestamp":1788268959456,"version":"build-2803163510"},"reference-count":37,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sci.","Brain Sciences"],"abstract":"<jats:p>Background\/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for the treatment of overweight and obesity because of their established efficacy in achieving clinically meaningful weight loss. However, concerns have emerged regarding their potential association with neuropsychiatric outcomes, including depressive and anxiety symptoms, manic or hypomanic symptoms, and suicidal ideation or behavior. This systematic review aimed to synthesize the available evidence on neuropsychiatric outcomes associated with GLP-1 RA use in adults with overweight or obesity. Methods: A systematic search of PubMed\/MEDLINE, Scopus, and Web of Science was conducted following PRISMA 2020 guidelines. Eligible studies included randomized controlled trials, longitudinal observational studies, and cross-sectional studies evaluating neuropsychiatric outcomes associated with GLP-1 RAs in adults with overweight or obesity. Risk of bias was assessed using RoB 2, ROBINS-I, and the Joanna Briggs Institute Critical Appraisal Checklist according to study design. Given the clinical and methodological heterogeneity of the included studies, findings were synthesized narratively in accordance with SWiM guidance, and certainty of evidence was assessed at the outcome level using GRADE. Results: Fourteen studies were included, comprising four randomized studies, nine longitudinal observational studies, and one analytical cross-sectional study. Randomized evidence showed no consistent worsening of depressive symptoms or imbalance in suicide-related outcomes, whereas observational findings were heterogeneous. For depression, observational HRs ranged from 0.63 to 2.95 across different populations and comparators, while randomized studies showed small or no between-group differences in depressive symptoms. For suicide-related outcomes, observational HRs\/aHRs ranged from 0.27 to 2.06, while suicidal ideation or behavior was uncommon in randomized studies and showed no consistent treatment imbalance. Anxiety-related findings were also heterogeneous, and manic or hypomanic symptoms were not systematically assessed. GRADE certainty was low for depressive symptoms and very low for anxiety and suicide-related outcomes. Conclusions: Current evidence does not demonstrate a consistent increase in adverse neuropsychiatric outcomes associated with GLP-1 receptor agonists in adults with overweight or obesity. Although some studies reported neutral or potentially beneficial associations, observational findings were heterogeneous, and the certainty of evidence was low or very low across the assessable outcomes. These findings do not establish a class-wide neuropsychiatric safety effect, particularly given differences among individual agents, study populations, and baseline psychiatric characteristics. Further prospective studies specifically designed to assess neuropsychiatric outcomes, including individuals with pre-existing psychiatric disorders, are warranted.<\/jats:p>","DOI":"10.3390\/brainsci16090926","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:41:18Z","timestamp":1788266478000},"page":"926","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2660-7416","authenticated-orcid":false,"given":"Carla","family":"Lubo","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Bustamante","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3729-8066","authenticated-orcid":false,"given":"Laura","family":"Quintana","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-431X","authenticated-orcid":false,"given":"Hernan F.","family":"Guillen-Burgos","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"},{"name":"Center for Clinical and Translational Research, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"},{"name":"Department of Psychiatry and Mental Health, Pontificia Universidad Javeriana, Bogot\u00e1 110111, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/advances\/nmy055","article-title":"Humans against obesity: Who will win?","volume":"10","author":"Caballero","year":"2019","journal-title":"Adv. Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000442721","article-title":"European guidelines for obesity management in adults","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obes. Facts"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"McIntyre, R.S. (Biol. Psychiatry, 2026). Glucagon-like peptide-1 receptor agonists for mood disorders and suicide risk, Biol. Psychiatry, in press.","DOI":"10.1016\/j.biopsych.2026.04.019"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Carmellini, P., Cuomo, A., Rescalli, M.B., and Fagiolini, A. (2025). GLP-1 receptor agonists in mood disorders: A psychiatric perspective. Life, 15.","DOI":"10.3390\/life15091422"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117192","DOI":"10.1016\/j.psychres.2026.117192","article-title":"The association between anhedonia and obesity: A systematic review","volume":"362","author":"Hajje","year":"2026","journal-title":"Psychiatry Res."},{"key":"ref_12","unstructured":"European Medicines Agency (2026, August 16). Meeting Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8\u201311 April 2024. Available online: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024."},{"key":"ref_13","unstructured":"U.S. Food and Drug Administration (2026, August 16). FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Medications, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-communications\/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: Post hoc analysis of the STEP 1, 2, 3, and 5 trials","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"24433","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1111\/dom.70393","article-title":"Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg","volume":"28","author":"Kuckuck","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., and Brennan, S.E. (2020). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. MetaArXiv.","DOI":"10.31222\/osf.io\/v7gm2_v1"},{"key":"ref_19","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2024). Cochrane Handbook for Systematic Reviews of Interventions, Version 6.5, Cochrane."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.11124\/JBIES-24-00523","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for analytical cross-sectional studies","volume":"24","author":"Barker","year":"2026","journal-title":"JBI Evid. Synth."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/dom.12963","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials","volume":"19","author":"Aroda","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/oby.70122","article-title":"Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: Post hoc analysis of the SURMOUNT programme","volume":"34","author":"Wadden","year":"2026","journal-title":"Obesity"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/dom.70215","article-title":"Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial","volume":"28","author":"Shukla","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/hm.HM-D-25-00125","article-title":"Changes in psychiatric symptoms, eating disorder behaviors, and health behaviors following six months of GLP-1 treatment for obesity: A pre-to-post-treatment study","volume":"10","author":"Rutledge","year":"2026","journal-title":"Heart Mind"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1111\/dom.70054","article-title":"Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study","volume":"27","author":"Tang","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00125-024-06243-z","article-title":"Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: A propensity-weighted, population-based cohort study","volume":"67","author":"Hurtado","year":"2024","journal-title":"Diabetologia"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Yu, W.-S., Huang, J.-Y., Lo, S.-C., Huang, C.-N., Yang, Y.-S., and Kornelius, E. (2025). Association of tirzepatide and the risk of suicide in a real-world cohort. Front. Psychiatry, 16.","DOI":"10.3389\/fpsyt.2025.1626103"},{"key":"ref_33","first-page":"1554","article-title":"Risk of depression with GLP-1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new-user, active-comparator cohort study","volume":"28","author":"Chang","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1111\/dom.70002","article-title":"Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population-based cohort study","volume":"27","author":"Her","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Witaszek, T., K\u0142oda, K., Mastalerz-Migas, A., and Babicki, M. (2024). Association between symptoms of depression and generalised anxiety disorder evaluated through PHQ-9 and GAD-7 and anti-obesity treatment in Polish adult women. Nutrients, 16.","DOI":"10.21203\/rs.3.rs-4289778\/v1"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: A systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","article-title":"Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: A narrative review","volume":"14","author":"West","year":"2025","journal-title":"Neurol. Ther."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/9\/926\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:01:37Z","timestamp":1788267697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/9\/926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["brainsci16090926"],"URL":"https:\/\/doi.org\/10.3390\/brainsci16090926","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}